Clearpoint Neuro Inc reports results for the quarter ended March 31 - Earnings Summary

• Clearpoint Neuro Inc CLPT.OQ reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -16 cents. The mean expectation of three analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -19 cents to -14 cents per share.

• Revenue rose 11.1% to $8.49 million from a year ago; analysts expected $8.20 million.

• Clearpoint Neuro Inc's reported EPS for the quarter was a loss of 22 cents​.

• The company reported a quarterly loss of $6.03 million.

• Clearpoint Neuro Inc shares had risen by 14.7% this quarter and lost 11.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

• Wall Street's median 12-month price target for Clearpoint Neuro Inc is $28.00

This summary was machine generated from LSEG data May 13 at 09:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)